Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-17
2005-05-17
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S011400
Reexamination Certificate
active
06894026
ABSTRACT:
Methods and compositions are provided for prophylaxis and treatment of breast cancer involving administration of a therapeutically effective amount of carbetocin and/or other long-acting oxytocin analogues. 1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin (carbetocin) and/or other long-acting oxytocin analogues are formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to inhibit initiation or growth of breast cancer in the patient. The carbetocin and/or other long-acting oxytocin analogues may also be formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to treat, prevent or alleviate the symptoms of a psychiatric disorder in the patient. Carbetocin may be administered prophylactically or to treat existing conditions in patients by a variety of administration modes, including intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery methods and formulations. Preferably, the carbetocin is administered to a mucosal surface of the patient via intranasal delivery. For this purpose, pharmaceutical compositions are provided for intranasal delivery that incorporate carbetocin in a powder or aqueous formulation for intranasal delivery.
REFERENCES:
patent: 5482931 (1996-01-01), Harris et al.
patent: 5798266 (1998-08-01), Quay et al.
patent: 6333313 (2001-12-01), Copland et al.
patent: 8809810 (1988-12-01), None
patent: 8910134 (1989-11-01), None
patent: 9808976 (1998-03-01), None
Cassoni, P. et al.., “Oxytonin inhibits proliferation of human breast cancer cell lines”, Virchows Archive. 425:467-472, 1994.*
Lipton, A. et al., “Acute inhibition of rat myometrial responses to oxytocin by tamoxifen stereoisomers and oestradiol”, J. Endocr. 103, 383-388, 1984.*
Stein, J., editor-in-chief, Internal Medicine, 4th Edition, Chapters 71-72, pp. 699-715, 1994.*
Boer et al., “Oxytocin in Obsessive Compulsive Disorder”, Peptides, vol. 13, pp. 1083-1085, 1992.*
Leckman, J. F. et al., “The Role of Central Oxytocin in Obsessive Compulsive Disorder and Related Normal Behavior”, Psychoneuroendocrinology, vol. 19, No. 8, pp. 723-749, 1994.*
Windholz, M. et al., Editor-in-Chief, The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 10thEdition, p. 1300, 1986.*
Windholz, M., Editor, The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 10thEdition, Compound No 8923, p. 1300, Jul. 21, 1986.*
Altemus et al., “Normal CSF Oxytocin and NPY Levels in OCD,”Biol. Psychiatry 45: 931-33, 1999.
Cassoni et al., “Oxytocin Inhibits Proliferation of Human Breast cancer Cell Lines,”Virchows Archiv. 425:467-472, 1994.
Cassoni et al., “Oxytocin and Oxytocin-Analogue F314 Inhibit cell Proliferation and Tumor Growth of Rat and Mouse mammary carcinomas,”Int. J. Cancer 66:817-820, 1996.
Cassoni et al., “Oxytocin Inhibits the Proliferation of MDA-MB231 Human Breast-Cancer CellsViaCyclic Adenosine Monophosphate and Protein Kinase A,”Int. J. Cancer 72:340-344, 1997.
den Boer and Westenberg, “Oxytocin in Obsessive Compulsive Disorder,”Peptides 13:1083-85, 1992.
Insel et al., “Oxytocin, Vasopressin, and Autism: Is There a Connection?,”Biol. Psychiatry 45:145-157, 1999.
Leckman et al., “The Role of Central Oxytocin in Obsessive Compulsive Disorder and Related Normal Behavior,”Psychoneuroendocrinology 19:723-749, 1994.
Leckman et al., “Elevated Cerebrospinal Fluid Levels of Oxytocin in Obsessive-compulsive Disorder,”Arch Gen Psychiatry 51:782-92, 1994.
Lipton et al., “Acute Inhibition of Rat Myometrial Responses to Oxytocin by Tamoxifen Stereoisomers and Oestradiol,”J. Endocr. 103:383-388, 1984.
Martin et al., “Cerebrospinal Fluid Levels of Oxytocin in Prader-Willi Syndrome: A Preliminary Report,”Biol. Psychiatric 44:1349-1352, 1998.
Modahl et al., “Plasma Oxytocin Levels in Autistic Children,”Biol. Psychiatric 43:270-277, 1998.
Atke et al., “Uterotonic Activity and Myometrial Receptor Affinity of 1-Deamino-1-Carwba-2-Tyrosine (O-Methyl)-Oxytocin,”Acta Endocrinol. 115:155-160, 1987.
Boucher et al., “Double-Blind, Randomized Comparison of the Effect of Carbetocin and Oxytocin on Intraoperative Blood Loss and Uterine Tone of Patients Undergoing Cesarean Section,”J. Perinatology 18:202-207, 1998.
Bussolati et al., “Immunolocalization and Gene Expression of Oxytocin Receptors in Carcinomas and Non-Neoplastic Tissues of the Breast,”Am. J. Pathol. 148:1895-1903, 1996.
Cobo, E., “Characteristics of the Spontaneous Milk Ejecting Activity Occurring During Human Lactation,”J. Perinat. Med. 21:77-85, 1993.
Cort et al., “Effect of Oxytocin and its Long-Acting Analog on Milk Let-down and Intramammary Pressure in Healthy Lactating Sows,”Am. J. Vet. Res. 43:1283-1285, 1982.
Dansereau et al., “Double-Blind Comparison of Carbetocin Versus Oxytocin in Prevention of Uterine Atony After Cesarean Section,”AM. J. Obstet. Gynecol. 180:670-676, 1999.
Engstrom et al., “Oxzytocin Receptor Binding and Uterotonic Activity of Carbetocin and Its Metabolites Following Enzymatic Degradation,”Eur. J. Pharmacol. 355:203-210, 1998.
Fay et al., “Oxytocin Does Not Induce A Rise in Intracellular Free Calcium in Human Breast Cancer Cells,”Res. Commun. Mol. Pathol. Pharmacol. 103:115-128, 1999.
Gonser, M., “Labor Induction and Augmentation with Oxytocin: Pharmacokinetic Considerations,”Arch. Gynecol. Obstet. 256:63-66, 1995.
Hunter et al.m “Effect of Carbetocin, A Long-Acting Oxytocin Analog on the Postpartum Uterus,”Clin. Pharmacol. Ther. 52:60-67, 1992.
Ito et al., “Investigation of the Oxytocin Recptor Expression in Human Breast Cancer Tissue Using Newly Established Monoclonal Antibodies,”Endocrinology 137:773-779, 1996.
Kimura et al., “Expression and Immunolocalization of the Oxytocin Receptor in Human Lactating and Non-Lactating Mammary Glands,”Human Reprod. 13: 2645-2653, 1998.
Mena, F., “Central Effects of Catecholamines Upon Mammary Contractility in Rats Are Neurally Mediated,”Neuroendocrinology 61:722-730, 1995.
Murrell, T.G.C. “The Potential for Oxytocin (OT) to Prevent Breast Cancer: A Hypothesis,”Breast Cancer Res. Treat. 35:225-229, 1995.
Murrell, “Epidemiological and Biochemical Support for a Theory on the Causes and Prevention of Breast Cancer,”Med. Hypotheses 36:389-396, 1991.
Nass et al., “The Biology of Breast Cancer,”Hematol. Oncol. North Am. 13:311-332, 1999.
Newton, N., “The Quantitative Effect of Oxytocin (Pitocin) on Human Milk Yield,”Ann. N.Y. Acad. Sci. 652:481-483.
Norström et al.,k “Contractile Effect of Oxytocin and 1-Deamino-1-Carba-2-Tyrosine (0-Methyl)-Oxytocin in Myometrial Tissue from Non-Pregnant and Term Pregnant Women,”Acta Endocrinol. 122:566-568, 1990.
Orhue, A., “Incremental Increases in Oxytocin Infusion Regimens for Induction of Labor at Term in Primigravidas: A Randomized Controlled Trial,”Obstet. Gynecol. 83:229-233, 1994.
Planchon et al., “Alteration of Prostaglandin E Receptors in Advanced Breast Tumor Cell Lines,”Mol. Cell. Endocrinol. 111:219-233, 1995.
Sapino et al., “Oxytocin Receptor Within the Breast: Biological Function and Distribution,”Anticancer Res. 18:2181-2186, 1998.
Sapino et al., “Oxytocin Enhance Myoepithelial Cell Differentiation and Proliferation in the Mouse Mammary Gland,”Endocrinology 133:838-842, 1993.
Satin et al., “Factors Affecting the Dose Response to Oxytocin for Labor Stimulation,”Am. J. Obstetl. Gynecol. 166:1260-1261, 1992.
Satin et al., “High-Dose Oxytocin” 20-Versus 40-Minute Dosage Interval,Obstet. Gynecol.83: 234-238, 1994.
Silcox, et al., “Transfer of Carbetocin into Human B
Atossa Healthcare Inc.
Graybeal Jackson Haley LLP
Jones Dwayne
LandOfFree
Long-acting oxytocin analogues for the treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Long-acting oxytocin analogues for the treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long-acting oxytocin analogues for the treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3388077